- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: CD55.
Displaying page 1 of 1.
EudraCT Number: 2018-003418-41 | Sponsor Protocol Number: NAV3-32 | Start Date*: 2020-05-18 | |||||||||||
Sponsor Name:Navidea Biopharmaceuticals Ltd | |||||||||||||
Full Title: A Comparison of Tc 99m Tilmanocept Quantitative Imaging with Immunohistochemical (IHC) Analysis of CD206 Expression in Synovial Tissue from Subjects Clinically Diagnosed with Rheumatoid Arthritis (RA) | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002082-38 | Sponsor Protocol Number: RG_11-123 | Start Date*: 2012-04-16 |
Sponsor Name:University of Birmingham | ||
Full Title: A study of the effects of Simvastatin on neutrophil function in elderly subjects | ||
Medical condition: We are investigating the effects of Simvastatin 80mg on neutrophil function (using in vitro studies of neutrophil function), in healthy elderly subjects as there is evidence to suggest that Simvast... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000169-60 | Sponsor Protocol Number: CA209-755 | Start Date*: 2017-05-23 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: A phase 2 study of nivolumab combined with daratumumab with or without low dose cyclophosphamide in relapsed/refractory multiple myeloma | |||||||||||||
Medical condition: relapsed/refractory multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001587-13 | Sponsor Protocol Number: RC21_0169 | Start Date*: 2021-10-01 |
Sponsor Name:CHU de Nantes | ||
Full Title: A multi-center open-label phase 2 study of Ixazomib, Iberdomide and dexamethasone in elderly patients with multiple myeloma at first relapse. | ||
Medical condition: Elderly patients with multiple myeloma at first relapse | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004268-36 | Sponsor Protocol Number: APL2-302 | Start Date*: 2018-10-01 | |||||||||||
Sponsor Name:Apellis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
Medical condition: PNH is an acquired, rare, clonal, non-malignant hematologic disease characterized by complement-mediated RBC hemolysis with or without hemoglobinuria, an increased susceptibility to thrombotic epis... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) ES (Completed) NL (Completed) FR (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003862-10 | Sponsor Protocol Number: Dara-Atra | Start Date*: 2016-04-01 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: A phase 1 and phase 2 study of daratumumab in combination with all-trans retinoic acid in relapsed/refractory multiple myeloma | |||||||||||||
Medical condition: relapsed/refractory multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-006163-31 | Sponsor Protocol Number: Hx-CD20-406 | Start Date*: 2006-05-16 | |||||||||||
Sponsor Name:Genmab A/S | |||||||||||||
Full Title: A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with B-cell Chronic Lymphocytic Leukemia who have failed fludarabine and alem... | |||||||||||||
Medical condition: B-cell Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) DE (Completed) CZ (Completed) DK (Completed) ES (Completed) NL (Prematurely Ended) IT (Completed) BE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
